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ABSTRACT 
Bone morphogenetic proteins 9 and 10 
(BMP9/BMP10) are circulating cytokines with 
important roles in endothelial homeostasis. The 
aim of this study was to investigate the roles of 
BMP9 and BMP10 in mediating monocyte-
endothelial interactions using an in vitro flow 
adhesion assay. Herein, we report that while 
BMP9/BMP10 alone had no effect on monocyte 
recruitment, at higher concentrations both 
cytokines synergised with Tumor necrosis factor-α 
(TNFα) to increase recruitment to the vascular 
endothelium. The BMP9/BMP10-mediated 
increase in monocyte recruitment in the presence 
of TNFα was associated with upregulated 
expression levels of E-selectin, VCAM-1 and 
ICAM-1 on endothelial cells. Using siRNAs to 
type I and II BMP receptors and the signaling 
intermediaries (Smads), we demonstrated a key 
role for ALK2 in the BMP9/BMP10-induced 
surface expression of E-selectin, and both ALK1 
and ALK2 in the upregulation of VCAM-1 and 
ICAM-1. The type II receptors, BMPR-II and 
ACTR-IIA were both required for this response, as 
was Smad1/5. The upregulation of cell surface 
adhesion molecules by BMP9/10 in the presence of 
TNFα was inhibited by LDN193189, which 
inhibits ALK2 but not ALK1. Furthermore, 
LDN193189 inhibited monocyte recruitment 
induced by TNFα and BMP9/10. BMP9/10 
increased basal IB- protein expression, but did 
not alter p65/RelA levels. Our findings suggest that 
higher concentrations of BMP9/BMP10 synergise 
with TNFα to induce the upregulation of 
endothelial selectins and adhesion molecules, 
ultimately resulting in increased monocyte 
recruitment to the vascular endothelium. This 
process is mediated mainly via the ALK2 type I 
receptor, BMPR-II/ACTR-IIA type II receptors, 
and downstream Smad1/5 signaling. 
 
INTRODUCTION 
The vascular endothelium is a key regulator of 
vascular homeostasis with important roles in 
regulating blood pressure, coagulation, leukocyte 
trafficking and angiogenesis (1-3). The normal 
vascular endothelium regulates the passage of 
circulating cells into the interstitial space through 
several mechanisms, including leukocyte 
recruitment and alterations in permeability. 
However, endothelial dysfunction initiates a series 
of events triggering aberrant endothelial activation 
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that can lead to chronic pathological permeability 
and leukocyte adherence (4), which contribute to 
cardiovascular diseases, including atherosclerosis.   
Chronic systemic inflammation is associated with 
many cardiovascular, rheumatological and 
respiratory diseases (5-7), principally through the 
pathological activation of the vascular 
endothelium. Inflammatory cytokines including 
Tumour necrosis factor alpha (TNFα) and 
interleukin-1β are elevated in atherosclerosis. This 
promotes the upregulation of endothelial-expressed 
cell surface proteins that mediate leukocyte 
adhesion, including P- and E-selectin, which are 
involved in the initial leukocyte capture, and 
ICAM- and VCAM-1, which regulate the firm 
adhesion and transmigration of leukocytes (8-10).  
Bone morphogenetic proteins (BMPs) are 
ligands belonging to the TGFβ superfamily. 
Aberrant BMP2, BMP4 and BMP6 signaling have 
been associated with the inflammation, fibrosis, 
calcification and osteogenesis that are associated 
with the pathophysiology of atherosclerosis (11-
17). Since BMP9 and BMP10 are potent mediators 
of endothelial function it is likely that they also 
contribute to the pathobiology of vascular diseases 
such as atherosclerosis. However, the role played 
by BMP9 and BMP10 in monocyte transmigration 
across the endothelium, one of the initiating steps 
in atherosclerosis, has not been studied. BMP9 is a 
key regulator of vascular quiescence (18,19), and 
has been shown to protect the endothelium through 
the inhibition of vascular permeability (20), 
endothelial proliferation (18), angiogenesis (21) 
and lymphangiogenesis (22,23). Whilst BMP9 has 
been more extensively characterised than BMP10, 
in cell culture experiments BMP10 regulates a 
similar set of genes as BMP9 (24) and BMP10 can 
substitute for BMP9 in a mouse model of postnatal 
retinal vascular remodelling (21). Moreover, 
similar to BMP9, BMP10 has been described as a 
mediator of flow-dependent arterial quiescence 
(25). These studies suggest an overlapping role and 
function for BMP9 and BMP10 in the vasculature.  
BMP serine-threonine kinase receptors 
form heterodimeric complexes consisting of type I 
and type II receptors (26). BMP9 and BMP10 
signal through type I and type II receptors 
expressed on endothelial cells, including the type I 
receptors, activin-like kinase (ALK)1 and ALK2, 
and the type II receptors, bone morphogenetic 
protein receptor 2 (BMPR-II encoded by BMPR2), 
activin receptor 2A (ACTR-IIA encoded by 
ACVR2A) and activin receptor 2B (ACTR-IIB 
encoded by ACVR2B) (24,27,28). Optimal BMP9 
and BMP10 signaling requires the type III 
auxiliary receptor endoglin, also expressed on 
endothelial cells (27). Mutations in BMP9 and its’ 
receptors underlie vascular diseases, namely 
hereditary hemorrhagic telangiectasia (ALK1, 
endoglin and BMP9) (29-31) and pulmonary 
arterial hypertension (ALK1, BMPR2) (32-34). 
Furthermore, endothelial deletion of Bmpr2 in 
mice enhances the development of atherosclerosis, 
suggesting an atheroprotective protective role for 
BMPR-II (35).     
Activated BMP receptors transduce their 
signal primarily through phosphorylation of 
Smad1, Smad5 and Smad8.  Following activation, 
Smads form heteromeric complexes with the 
common partner Smad, Smad4 (26). These 
complexes translocate to the nucleus and regulate 
the expression of numerous genes through binding 
to promoter regions, usually in complex with other 
transcription factors. The best characterised targets 
of BMP/Smad signaling are the inhibitor of 
differentiation (ID) genes which possess Smad 
binding elements in their promoters (36).  
BMP9 signaling has been implicated 
previously in neutrophil recruitment to the 
endothelium, both directly (37) and indirectly (38-
40). BMP9 has previously been shown to 
upregulate E-selectin and VCAM-1 on LPS-
stimulated blood outgrowth endothelial cells (37) 
and endothelial cell surface expressed endoglin 
enhances leukocyte recruitment through the 
activation of β1-integrins expressed on the surface 
of leukocytes (40). Furthermore, BMPR2 deficient 
endothelium shows impaired leukocyte recruitment 
(38,39), thus further implicating BMP9 signaling 
in the process of leukocyte recruitment. 
Monocyte recruitment to the vascular 
endothelium is a key mediator of the progression 
of atherosclerotic lesions (41,42). Whilst there is a 
growing body of evidence associating BMP9 
signaling with neutrophil recruitment, the role of 
BMP9 and BMP10 in monocyte recruitment to the 
vascular endothelium has yet to be reported. In the 
current study we show, using an in vitro flow 
adhesion assay that both BMP9 and BMP10, in a 
concentration-dependent manner, synergistically 
enhance monocyte recruitment to TNFα-stimulated 
human aortic endothelial cells (HAECs). This 
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occurs through the upregulation of E-selectin, 
VCAM-1 and ICAM-1 on HAECs, and mainly via 
the type I receptor ALK2, the type II receptors 
BMPR-II/ACTR-IIA, and the downstream 
mediators Smad1/5. 
 
RESULTS 
BMP9 and BMP10 increase monocyte recruitment 
to TNFα-treated HAECs in a concentration-
dependent manner - First, we investigated the role 
of BMP9 and BMP10 on monocyte recruitment to 
the vascular endothelium using an in vitro flow 
adhesion assay, which enables the quantification of 
real-time interactions between endothelial cells and 
leukocytes under conditions of physiological flow. 
As BMP9 has been reported to circulate at 
concentrations between 2-12ng/ml in humans 
(18,43), we exposed the endothelium to BMP9 or 
BMP10 at concentrations ranging from 0-5ng/ml 
prior to the addition of TNFα, then assessed 
monocyte recruitment. Negligible monocyte 
recruitment was observed in HAECs treated with 
BMP9 (Figure 1A,B) or BMP10 (Figure 1A,C) 
alone. Whilst TNFα treatment, as previously 
reported (2,44,45)), induced some monocyte 
recruitment to HAEC monolayers (Figure 1A-C), a 
synergistic increase in total monocyte recruitment 
was observed when TNFα-stimulated HAECs were 
pre-treated with BMP9 or BMP10 at 
concentrations equal to or higher than 1.5ng/ml 
(Figure 1A-C). Pre-treatment of the vascular 
endothelium with BMP9 or BMP10 did not affect 
the percentage of rolling, arrested or transmigrated 
monocytes (Figure 1D,E). Only minimal monocyte 
rolling was observed in these experiments, 
suggesting that this process is rapidly followed by 
arrest and transmigration. Maximal monocyte 
recruitment was observed when TNFα-stimulated 
HAECs were pre-treated with BMP9 or BMP10 at 
a concentration of 5ng/ml, consequently, this 
concentration was used in all subsequent 
experiments. To examine whether this response 
was restricted to aortic cells, we also assessed the 
influence of BMP9 and BMP10 on TNFα–
dependent recruitment of monocytes to blood 
outgrowth endothelial cell (BOEC) monolayers 
(46). Similar to HAECs, BMP9 and BMP10 did 
not influence monocyte adhesion to BOECs, but 
enhanced the recruitment observed in response to 
TNFα (Figure 1F,G). Taken together, these data 
show that both BMP9 and BMP10 synergise with 
TNFα to enhance monocyte recruitment to the 
vascular endothelium in a concentration-dependent 
manner, at or above 1.5ng/ml.  
  
BMP9 and BMP10 increase expression of 
adhesion molecules and BMP2 in TNFα-treated 
HAECs - Next, we used qPCR and flow cytometry 
to identify whether pre-treatment with BMP9 or 
BMP10 increased expression of the endothelial 
selectins and adhesion molecules involved in 
monocyte recruitment in TNFα-stimulated HAECs. 
In accordance with previous studies (47-50), TNFα 
induced gene and surface protein expression of E-
selectin, VCAM-1 and ICAM-1, which were 
synergistically increased in HAECs (Figure 2A-F 
and Figure S1) or BOECs (Figure S2A-C) pre-
treated with either BMP9 or BMP10 (5ng/ml). 
BMP9 and BMP10 alone had no effect on the 
expression of these adhesion molecules. P-selectin 
was not detected on HAECs with any of the 
treatments (data not shown).  
Since BMP2, BMP4 and BMP6 have been 
previously implicated in inflammation, fibrosis and 
osteogenesis (11-13), we next investigated whether 
treatment with BMP9 or BMP10 increased 
expression of these ligands in HAECs. BMP9 and 
BMP10 alone induced the expression of BMP2 by 
3-4-fold in HAECs, whereas TNFα exerted a weak 
induction (Figure 2G). However, pre-treatment 
with either BMP9 or BMP10 prior to TNFα-
stimulation accentuated BMP2 expression in 
HAECs (Figure 2G). BMP4 was slightly repressed 
by BMP9, BMP10 and TNFα, whereas BMP6 
expression did not change with any of the 
conditions tested (Figure 2H, I). Taken together, 
these data reveal that both BMP9 and BMP10 
synergise with TNFα to up-regulate endothelial-
expressed molecules involved in leukocyte 
recruitment, in addition to BMP2, a factor 
previously implicated in endothelial inflammation. 
 
BMP6 increases the surface expression of 
adhesion molecules on TNFα-treated HAECs - 
BMP6 has been previously described as a factor 
that induces endothelial inflammation (11). BMP6 
transduces signaling predominantly via the type I 
receptor ALK2, and not ALK1 (11,51). Therefore, 
we investigated the potential role of BMP6/ALK2 
in inducing E-selectin, VCAM-1 and ICAM-1 
surface expression in HAECs. BMP6 pre-treatment 
induced a marked upregulation of the surface 
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expression levels of E-selectin, VCAM-1 and 
ICAM-1 in TNFα-treated HAECs (Figure 3A, B, 
C). The upregulation in E-selectin and VCAM-1 in 
response to BMP6 was completely abrogated by 
the use of a neutralising anti-BMP6 antibody 
(Figure 3A, B). Treatment with the BMP6 targeted 
antibody did not cause any further reduction in 
ICAM-1 (Figure 3C), indicating that ICAM-1 
surface protein expression is regulated through a 
different mechanism to E-selectin and VCAM-1. 
We next determined whether the 
BMP9/BMP10-induced upregulation of adhesion 
molecules was mediated by BMP6. Treatment with 
the anti-BMP6 neutralising antibody likewise had 
no effect on the surface expression levels of 
adhesion molecules induced by BMP9, BMP10 
and TNFα treatments, indicating that this process 
was not mediated by BMP9 or BMP10 (Figure 3D-
H). Collectively, these data imply a dominant role 
for ALK2 mediated effects of BMPs in the 
upregulation of surface expression levels of 
endothelial adhesion molecules. 
 
The role of type I receptors in BMP9- and BMP10-
induced expression of adhesion molecules – 
Expression analysis for the BMP type I receptors 
in HAECs revealed that BMP9 and BMP10 
induced the expression of ALK1 and ALK2, with 
little effect on ALK3 (Fig S3A-C). ALK6 was not 
expressed. Addition of TNFα slightly reduced the 
expression of ALK1, but not ALK2. To determine 
the BMP type I receptors mediating the BMP9- 
and BMP10-induced upregulation in adhesion 
molecules in response to TNFα, we performed 
siRNA knockdown of ALK1 and ALK2 and 
assessed surface expression of adhesion molecules. 
The dependence of each adhesion molecule on 
ALK1 or ALK2 was different. The increase in cell 
surface E-selectin expression observed in HAECs 
pre-treated with BMP9 or BMP10 prior to TNFα 
was inhibited by ALK2 knockdown, but not ALK1 
knockdown (Figure 4A), suggesting a marked 
ALK2 dependence of E-selectin regulation by 
BMP9 or BMP10 in these experiments. 
Knockdown of ALK1 together with ALK2 did not 
impact further on E-selectin expression. For 
VCAM-1 individual siRNA knockdown of ALK1 
and ALK2 substantially impaired BMP9- and 
BMP10- induced VCAM-1 expression, and their 
combined knockdown further inhibited surface 
VCAM-1 expression (Figure 4B). For ICAM-1, 
only combined ALK1 and ALK2 knockdown 
resulted in impaired BMP9- and BMP10-induced 
surface ICAM-1 expression (Figure 4C). The 
knockdown efficiency of siALK1 and siALK2 in 
HAECs confirmed >85% reduction in mRNA 
levels of the corresponding target gene (Figure 
S3D,E). We also confirmed that siALK1, but not 
siALK2, reduced the ID1 induction by BMP9 and 
BMP10 in HAECs (Fig S4). These data show that 
ALK2 is essential for BMP9- and BMP10-induced 
E-selectin expression, whilst either ALK1 or 
ALK2 can increase VCAM-1 expression. ICAM-1 
requires both ALK1 and ALK2 for upregulation in 
TNFα-stimulated HAECs.  
To explore further the role of type I 
receptors in the BMP9/BMP10-induced expression 
of adhesion molecules in TNFα-stimulated 
HAECs, we employed LDN193189, a cell 
permeable small molecule inhibitor of BMP type I 
receptors. LDN193189 inhibits ALK2 with an IC50 
of 5nM, and ALK3 with an IC50 of 30nM, but has 
no effect on ALK1 in cells (52). LDN193189 also 
inhibits ACTR-IIA and ACTR-IIB (53).  
LDN193189 did not affect basal responses. 
However, pre-treatment of HAECs with 
LDN193189 decreased the BMP9 or BMP10-
induced upregulation of E-selectin and VCAM-1 
(Figure 5A-B). ICAM-1 surface expression levels 
were only slightly decreased after LDN193189 
treatment (Figure 5C). Furthermore, LDN193189 
reduced monocyte recruitment induced by BMP9 
or BMP10 treatment to the level of TNFα-only 
stimulation (Figure 5D, E). 
 
The role of BMP type II receptors in the BMP9- 
and BMP10-induced expression of adhesion 
molecules - As BMPR2 deficiency is associated 
with pulmonary arterial hypertension (PAH) 
(32,33) and more recently with atherosclerosis 
(35), we investigated the role of the BMP Type-II 
receptors in mediating the expression of adhesion 
molecules. Expression analysis revealed that 
BMP9 and BMP10 induced the expression of 
BMPR2, but not ACVR2A or ACVR2B (Fig S5A-
C). TNFα slightly, but non-significantly reduced 
the expression of BMPR2 (Fig S5A). Transfection 
of siBMPR2 and siACVR2A, both individually and 
in combination, attenuated the BMP9- and 
BMP10-induced expression of E-selectin (Figure 
6A) and VCAM-1 (Figure 6B) in TNFα-stimulated 
HAECs. In contrast, individual knockdown of 
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BMPR2 and ACVR2A had no impact on ICAM-1 
expression, whereas combined knockdown of these 
receptors did impair ICAM-1 expression (Figure 
6A-C). The knockdown efficiency for siBMPR2 
and siACVR2A in HAECs were again >85% 
(Figure S5D,E).  
 
Smad1 and Smad5 mediate the BMP9- and 
BMP10-induced expression of adhesion molecules 
on TNFα-treated HAECs - To investigate the 
involvement of Smad1 and Smad5 (26,54) in 
BMP9/BMP10-induced up-regulation of adhesion 
molecules we employed siRNA knockdown. 
Unexpectedly, the TNFα–induced expression of 
VCAM-1, ICAM-1, and E-selectin was inhibited 
by SMAD1/5 knockdown, in keeping with the 
possibility that induction of BMP2 by TNFα was 
contributing to increased expression of these 
adhesion molecules (Figure 7A-C). BMP9- and 
BMP10-induced expression of E-selectin (Figure 
7A) and VCAM-1 (Figure 7B) in TNFα-stimulated 
HAECs was markedly impaired upon SMAD1 and 
SMAD5 knockdown, both individually and in 
combination. ICAM-1 expression was only 
inhibited when SMAD1 and SMAD5 were 
knocked-down in combination (Figure 7C). 
SMAD1 and SMAD5 siRNA knockdown efficiency 
was confirmed by qPCR and showed an 85% 
reduction of the target gene (Figure S6A,B).  
Since Smad2 and Smad3 have also been 
described as mediators of BMP9 signaling (28,55), 
we also employed siRNAs targeting SMAD2 and 
SMAD3 (Figure S6C,D). Knockdown of SMAD2 
and SMAD3 individually or in combination did not 
alter the BMP9- or BMP10-induced surface 
expression of adhesion molecules in HAECs 
(Figure S3). Collectively, these data show that 
Smad1/5, but not Smad2/3, are essential to the 
BMP9- and BMP10-induced expression of E-
selectin, VCAM-1 and ICAM-1 in TNFα-
stimulated HAECs. 
 
BMP9 and BMP10 increase IκB-α protein levels, 
but do not alter p65/RelA levels or 
phosphorylation.  TNFα is known to mediate the 
expression of cell surface adhesion receptors via 
the NF-κB pathway (10). We examined whether 
BMP9 or BMP10 mediated changes in the levels or 
phosphorylation of the canonical signalling 
proteins, IκB-α and p65. Both BMP9 9and BMP10 
increased basal IκB-α protein levels (Fig 8A,B), 
without any impact on IκB-α phosphorylation or 
on levels or Serine-536 phosphorylation of p65. 
These data suggest that BMP9/10 prime 
endothelial cells for TNFα responsiveness by 
increasing IκB-α levels. 
 
DISCUSSION 
The present study investigated whether 
BMP9 or BMP10, important circulating regulators 
of vascular quiescence, play a role in monocyte 
recruitment to the vascular endothelium. Although 
BMP9 or BMP10 alone had no effect on monocyte 
recruitment, in the presence of TNF both BMPs 
synergistically and in a concentration-dependent 
manner increased monocyte recruitment and 
transmigration. Using siRNA knockdown of type I 
receptors and a small molecule inhibitor, we show 
that these effects are predominantly mediated by 
ALK2 and also involve BMPR-II, ACT-RIIA, and 
the downstream signaling intermediaries, Smad1/5. 
The potentiation of TNFmediated 
monocyte recruitment was observed only at higher 
concentrations of BMP9 or BMP10, but was also 
readily induced by BMP6, a ligand with high 
affinity for ALK2. Knockdown of ALK1 and ALK2 
in HAECs demonstrated that the BMP9/10-
dependent potentiation of the TNFα-stimulated E-
selectin expression  was entirely ALK2-dependent, 
whereas VCAM-1 was partially dependent on each 
receptor and ICAM-1 was only altered when both 
ALK1 and ALK2 were knocked down. Our data 
suggest a contribution from both ALK1 and ALK2 
receptors in mediating the overall response but a 
dominance of the ALK2 receptor in the 
potentiation of the BMP9 or BMP10-induced 
monocyte recruitment to the TNFα-stimulated 
HAECs. BMP9 and BMP10 both induced the 
expression of ALK1 and ALK2. The role of these 
receptors in atherosclerosis is intriguing, as the 
expression of both ALK1 and ALK2 is induced by 
HDL (56). Moreover, ALK1 mediates endothelial 
uptake of LDL, but not oxidised LDL in LDLR-
deficient mice, suggesting a role for ALK1 in 
normal endothelial lipid metabolism rather than the 
pathogenesis of atherosclerosis (57).  
To further investigate the role of type I 
receptors we employed a small molecule inhibitor 
of ALK2 and ALK3, LDN193189. LDN193189 
weakly inhibits ALK4, ALK5, ALK7, ACTR-IIA 
and ACTR-IIB (53) at the concentration used in 
this study but does not inhibit ALK1 (52). The 
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results confirm that the monocyte recruitment and 
induction of E-selectin, VCAM-1 and ICAM-1 
induced by BMP9 or BMP10 in TNFα-treated 
HAECs is largely independent of ALK1. Our 
findings also show that BMP9 and BMP10 
synergise with TNFα to induce expression of 
BMP2, which is a known regulator of endothelial 
inflammation and plays a role in atherosclerosis. 
Increased levels of BMP2 and BMP4 have been 
observed in atherosclerotic plaques (14-17,58). 
Once upregulated, BMP2 and BMP4 induce an 
inflammatory phenotype in endothelial cells, which 
results in leukocyte adhesion in vitro. BMP4 is 
increased in response to a high fat diet (a risk 
factor for atherosclerosis), which then up-regulates 
BMP2 levels (15). Furthermore, enhanced BMP2 
activity has been implicated in triggering and 
accelerating vascular calcification (14,15). We and 
others have shown previously that TNFα increases 
endothelial expression of BMP2 but not BMP4 
(12,59) and that BMP2 expression in endothelial 
cells can be activated by inflammatory stimuli in a 
NF-κB-dependent manner (59,60). In our current 
study neither TNFα, BMP9, nor BMP10 alone 
impacted on the expression of BMP2, BMP4 or 
BMP6 in HAECs. However, HAECs that were 
treated with BMP9 or BMP10 in the presence of 
TNFα showed a synergistic increase in BMP2 
expression, providing further evidence that BMP9 
and BMP10 are not themselves pro-inflammatory, 
but instead, might prime the vascular endothelium 
to mount a more intense response upon stimulation 
with an inflammatory cytokine such as TNFα. 
Chronic TNFα exposure reduces BMPR2 
expression in endothelial cells and can alter BMP 
signalling (59). Even in this acute study, low 
concentrations of TNFα reduced basal BMPR2 
expression, whilst cell surface E-selectin, ICAM-1 
and VCAM-1 were enhanced.  Moreover, both  
type II receptors, BMPR-II and ACT-RIIA, are 
essential for BMP9- and BMP10-induced 
expression of E-selectin and VCAM-1 in TNFα-
stimulated HAECs. BMPR-II has been implicated 
previously in leukocyte-endothelial interactions 
(38,39) and BMPR2 deficiency is associated with 
several inflammatory vascular pathologies 
including PAH (32,33)  and atherosclerosis (35). 
However, there is limited previous information on 
the role of ACT-RIIA in the regulation of 
endothelial-expressed selectins or adhesions 
molecules or the process of leukocyte recruitment 
(28). These findings provide further insight into the 
role of endothelial-expressed BMP type II 
receptors in maintaining endothelial homeostasis. 
We questioned whether the mechanism of 
the enhanced TNFα response in the presence of 
BMP9/10 might be due to their effect on the NF-
κB pathway, the main pathway known to induce 
endothelial adhesion molecules (10). We identified 
that BMP9/10 increased IκB-α protein levels, but 
that the rate of IκB-α phosphorylation and 
degradation are not altered. This implies that the 
cells are primed for the TNF-α response by 
BMP9/10. Although we did not observe changes in 
p65/RelA levels or Ser-536 phosphorylation, the 
NF-κB family members are activated by 
phosphorylation at several Serine residues, so the 
IκB-α priming may be associated with a different 
family member and/or different phosphorylation 
sites (61). 
In the present study, we have shown that 
BMP9- and BMP10-induced E-selectin, VCAM-1 
and ICAM-1 expression in TNFα-stimulated 
HAECs is regulated through the canonical BMP 
mediators, Smad1/5 and not Smad2/3. This 
correlates with our previous study which reported 
that Smad1/5 activation was required for BMP9-
induced expression of E-selectin and VCAM-1 in 
LPS-stimulated endothelial cells (37). Smad1/5 has 
also been reported to mediate the expression of 
pro-atherogenic genes that promote atherosclerotic 
plaque stability in monocyte-derived monocytes 
(62). Moreover, inhibition of BMP signaling using 
LDN193189 attenuated Smad1/5 activation and 
reduced endothelial inflammation and calcification 
in  atherosclerosis mouse models (63,64), thus 
further supporting our findings that Smad1/5 plays 
a key role in regulating endothelial homeostasis 
through the expression of selectins and adhesion 
molecules. 
Whilst BMP9 has been more extensively 
characterised than BMP10, there is evidence to 
suggest that BMP9 and BMP10 can perform 
overlapping roles. This has been seen in vitro 
whereby BMP9 and BMP10 regulate the 
expression of a similar set of genes in human 
microvascular endothelial cells (24). Further, both 
BMP9 and BMP10 are required for complete 
closure of the ductus arteriosus (65), and BMP10 
can compensate for the absence of BMP9, in 
BMP9 knockout mice during retinal 
vascularisation (21). However, Chen and 
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colleagues have shown that BMP9 is not able to 
substitute for BMP10 during cardiac development 
in mice (66), indicating a distinct role for BMP10 
in cardiogenesis. 
Monocyte transmigration across the 
endothelium is a normal physiological process but 
this process can lead to vascular pathologies and 
promote atherosclerosis if exaggerated. Here we 
show that treatment alone with either BMP9 or 
BMP10 (even at concentrations ≥1.5ng/ml) had no 
impact on monocyte recruitment in a flow 
adhesion assay. However, at concentrations 
≥1.5ng/ml BMP9 and BMP10 behave in a near 
identical manner to synergise with TNFα to 
upregulate BMP2 expression and to enhance 
monocyte adhesion and transmigration in HAECs 
predominantly through ALK2, BMPR-II/ACT-
RIIA and Smad1/5 signaling. We propose that the 
beneficial effects of BMP9 or BMP10 as vascular 
quiescent factors could be subverted in the 
presence of inflammatory mediators such as TNFα 
(59), contributing to pathological levels of 
monocyte recruitment; this in turn might stimulate 
foam cell development, inflammatory cytokine 
production and atherosclerotic plaque development 
and calcification. Our findings provide further 
insight into how BMP signaling mediates 
endothelial homeostasis and the mechanisms by 
which BMPs impact on cardiovascular disease. 
 
EXPERIMENTAL PROCEDURES 
Reagents, primers and antibodies-Cell culture 
reagents: BMP6, BMP9, BMP10 (R&D Systems), 
LDN193189 used at a working concentration of 
250 nM (stock resuspended in DMSO at 5mM, a 
kind gift from Professor Paul Yu, Department of 
Medicine, Harvard University) EGM-2 BulletKit 
(Lonza), fetal bovine serum (FBS) (Sigma-
Aldrich), trypsin (Sigma-Aldrich), Histopaque 
1077 and 1119 (Sigma-Aldrich), Dulbecco’s 
phosphate buffered saline (PBS) with Ca
2+
, Mg
2+
 
(Sigma-Aldrich), albumin bovine fraction (BSA) V 
solution 7.5% (Sigma-Aldrich), MACS separation 
system (Miltenyi Biotec), LS columns (Milteny 
Biotec) and CD14 microbeads (Milteny Biotec). 
siRNA transfection reagents: DharmaFECT1™ 
(Dharmacon), ON-TARGETplus™ siRNA Pools 
(Dharmacon), namely siALK1, siALK2, siSMAD1, 
siSMAD2, siSMAD3, siSMAD5, siBMPR2, 
siACVR2A, siACVR2B and non-targeting siRNA 
Pool (siCP). Flow cytometry reagents: anti-hE-
selectin fluorescein conjugated mouse IgG1 (anti-
human E-selectin-FITC, R&D Systems), 
allophycocyanin (APC) mouse anti-human CD54 
(anti-human ICAM-1-APC, BD Pharmingen) and 
PE/Cy5 anti-human CD106 (anti-human VCAM-1-
PECy5, BioLegend). Flow cytometry isotype 
control antibodies: mouse IgG1 isotype control 
fluorescein (R&D Systems), APC-mouse IgG1 
(BD Pharmingen) and PE/Cy5 mouse IgG1 isotype 
control (BioLegend). Western blotting antibodies: 
IκB-α mouse mAb, phospho-Ser32/36-IκB-α rabbit 
Ab, p65/RelA rabbit mAb or phospho-Ser536-p65 
rabbit Ab (Cell Signaling Technologies).  
Quantitative polymerase chain reaction (qPCR) 
reagents: QuantiTect Primer Assays (Qiagen) 
namely Hs-ACVRL1_1_SG (ALK1), 
Hs_ACVR1_1_SG (ALK2), SMAD2, SMAD3, 
ACVR2A. Primer sequences: BMPR2 forward 5’-
CAAATCTGTGAGCCCAACAGTCAA-3’, 
BMPR2 reverse 5’-GAGGAAGAATAATCTGGA 
TAAGGACCAAT-3’, SMAD1 forward 5’-
TAGAAAGCCCTGTACTTCCTC-3’, SMAD1 
reverse 5’-GGTTGCTGGAAAGAATCTGG-3’, 
SMAD5 forward  5’-GAGAGTCCAGTCTTACCT 
CC-3’, SMAD5 reverse 5’-GGAAAGAATCTGGA 
AACGTG-3’, PBGD forward 5’- 
AGCTATGAAGGATGGGCAAC-3’, PBGD 
reverse 5’-TTGTATGCTATCTGAGCCGTCTA-
3, B2M forward 5’-CTCGCGCTACTCTCTCTTT 
C-3’, B2M reverse 5’-CATTCTCTGCTGGATGA 
CGTG-3, HPRT forward 5’- GCTATAAATTCTT 
TGCTGACCTGCTG-3’, HPRT reverse 5’- 
AATTACTTTATGTCCCCTGTTGACTGG-3. 
ROX reference dye (Invitrogen), SYBRGreen 
JumpStart Taq ReadyMix (Sigma-Aldrich)  
 Endothelial cell culture-Human aortic 
endothelial cells (HAECs) were purchased from 
PromoCell and maintained in EGM2-mv (Lonza) 
with 5% FBS. HAECs were cultured at 37°C in a 
5% CO2 humidified atmosphere and used in 
experiments at passages 4-6. HAECs were treated 
with BMP6, BMP9, BMP10, or with 
LDN193189 with the indicated concentrations for 
16 h prior stimulation with TNFα (0.05ng/ml; 4 h). 
Blood outgrowth endothelial cells (BOECs) were 
generated from peripheral blood of control 
volunteers as described previously (46). Full 
informed written consent was obtained under 
ethical approval from the Huntington Local 
Research Ethics Committee.    
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 Monocyte isolation-Blood samples were 
derived from healthy volunteers after giving 
informed consent, according to the protocol 
approved by the Cambridge Research Ethics 
Committee (06/Q018/218). Two-step density 
gradients of Histopaque 1119 and 1077 (Sigma) 
were used to isolate peripheral blood mononuclear 
cells (PBMCs). CD14
+ 
monocytes were isolated 
from PBMCs through positive selection using 
magnetic-activated cell sorting (MACS) as per the 
manufacturer’s instructions. CD14+ monocytes 
were resuspended at a cell density of 1 x 10
6
 
cells/ml in 0.15% BSA in PBS (with Ca
2+
 and 
Mg
2+
). 
 siRNA transfection - HAECs were 
transfected with siRNA at 10 nM final 
concentration, using DharmaFECT1™ transfection 
reagent, following the manufacturer’s instructions, 
48 hours prior to their use in cell culture 
experiments. 
Monocyte-endothelial interactions under 
flow-An in vitro flow adhesion assay was used to 
assess endothelial-monocyte interactions as 
previously described (67). The microslide (μ-Slide 
VI
0.4
; Ibidi), containing the HAEC monolayer was 
connected to cell and wash reservoirs by silicon 
tubing and a valve enabled switching between the 
two reservoirs with continuous flow. The flow rate 
of 1 x 10
6
 monocytes/ml for 4 minutes, equivalent 
to a wall shear stress of 0.1 Pascals, was controlled 
using a glass syringe attached to a withdrawal 
pump. Monocyte-endothelial interactions were 
visualised using time lapse imaging at 6 min post 
the initial monocyte bolus using a phase contrast 
microscope, placed within a Perspex 
environmental chamber at 37°C. Quantification of 
monocyte behaviour including rolling, arrest and 
transmigration was performed offline using 
ImagePro software. 
Flow cytometric analysis of surface 
proteins-Flow cytometric analysis of endothelial 
cell surface adhesion proteins was performed as 
previously described (34) using anti-human E-
selectin-FITC, anti-human VCAM-1-PE-Cy5 and 
anti-human ICAM-APC with corresponding 
conjugated isotype controls. Analysis was 
performed using a BD FACSCanto™ II (BD 
Bioscences) and quantification was performed 
using FlowJo software. 
Quantitative polymerase chain reaction 
(qPCR)-An RNAeasy Mini kit (Qiagen) was used 
to extract the total RNA extracted from HAECs. 
mRNA expression of the genes of interest was 
assessed using SYBRGreen Jumpstart Taq 
ReadyMix, ROX reference dye and primers 
(Quantitect Primer Assays or in-house designed 
primers) in a 384 well QuantStudio 6 Flex 
(Applied Biosystems, Life Technologies). The 
∆∆Ct method was used for quantification. 
Western Blotting – HAECs were seeded in 
6cm dishes and grown to confluence. Cells were 
then incubated in EBM2 (Lonza) with 0.1% FBS 
(0.1% FBS) for 2 hours and then treated with 
BMP9, BMP10 or 0.1% FBS for 16h. Cells were 
then treated with TNFα (0.05ng/ml) or 0.1% FBS 
for 15min or 30min. Cells were snap-frozen and 
lysed in 250 mM Tris-HCl, pH 6.8, 4% SDS, 20% 
v/v glycerol containing an EDTA-free protease 
inhibitor cocktail (Roche, West Sussex, UK). 
Lysates were immunoblotted for the relevant 
proteins. 
Statistical analysis-Comparisons between 
two groups were made using an unpaired student t-
test. Comparisons between three or more groups 
were performed using one-way ANOVA with 
Tukey’s multiple comparisons. A probability (p 
value) smaller than 0.05 was considered 
statistically significant. Normality of data 
distribution was assessed using a D'Agostino & 
Pearson omnibus normality test. Data are presented 
as the mean ± the standard error of the mean 
(SEM). 
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FIGURES 
 
FIGURE 1. BMP9 and BMP10 increase monocyte recruitment to TNFα-stimulated human aortic 
endothelial cells (HAECs) in a concentration-dependent manner. HAECs were treated with BMP9 
and BMP10 16h prior to TNFα treatment (0.05ng/ml, 4 h). Monocytes were perfused over TNFα-
stimulated HAECs in a flow adhesion assay in the presence of media alone, BMP9 or BMP10. (A) 
Representative images of HAEC monolayers that were untreated, or treated with BMP9 (5ng/ml), BMP10 
(5ng/ml), TNFα, BMP9+TNFα or BMP10+TNFα. Adherent monocytes are the bright phase cells (white 
arrow) and transmigrated monocytes shown as the smaller dark phase cells (black arrow). Experiments 
were performed in triplicate and the data are representative of n=3 biological repeats. (B-C) 
Concentration-response analysis of the recruitment of monocytes to HAEC monolayers, in the presence or 
absence of TNFα, with increasing concentrations of (B) BMP9 (0-5ng/ml) and (C) BMP10 (0-5ng/ml).  
(D-E) Monocyte behaviour (rolling – clear bar, adherence –grey bar and transmigration – black bar) was 
expressed as a percentage of total recruitment to TNFα-stimulated HAECs in the presence of (D) BMP9 
and (E) BMP10. (F) Analysis of the recruitment of monocytes to BOEC monolayers, treated with 5ng/ml 
of BMP9 or BMP10, in the presence or absence of TNFα. (G) Monocyte behaviour (rolling – clear bar, 
adherence –grey bar and transmigration – black bar) was expressed as a percentage of total recruitment to 
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TNFα-stimulated BOECs in the presence of BMP9 or BMP10.  Error bars represent ± S.E.M. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001. 
 
FIGURE 2. BMP9 and BMP10 increase the expression of E-selectin, VCAM-1, ICAM-1 and BMP2 
in TNFα-stimulated human aortic endothelial cells (HAECs). HAECS were treated with BMP9 or 
BMP10 (5ng/ml, 16 h) prior to TNFα treatment (0.05ng/ml, 4 hours).  Expression of (A) SELE (E-
selectin), (B) VCAM1 and (C) ICAM1 mRNA assessed using qRT-PCR. Surface expression of (D) E-
selectin (FITC-conjugated anti-human E-selectin), (E) VCAM-1 (PE-Cy5-conjugated anti-human 
VCAM-1) and (F) ICAM-1 (APC-conjugated anti-human ICAM-1) was assessed using flow cytometry. 
Data are shown as median fluorescence intensity (MFI) expressed as fold change relative to untreated 
HAECs. Expression of (G) BMP2, (H) BMP4 and (I) BMP6 mRNA assessed using qRT-PCR. 
Experiments were performed in triplicate and the data are representative of n=3 biological repeats. Error 
bars represent ± S.E.M. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
 
FIGURE 3. BMP6 increases the expression of E-selectin, VCAM-1 and ICAM-1 in TNFα-stimulated 
human aortic endothelial cells (HAECs). HAECS were treated with a BMP6 neutralising antibody 
(BMP6 Ab) 60 min prior to the addition of BMP6 (25ng/ml, 16 h) followed by TNFα (0.05ng/ml; 4 h), 
Surface expression of (A) E-selectin (FITC-conjugated anti-human E-selectin), (B) VCAM-1 (PE-Cy5-
conjugated anti-human VCAM-1) and (C) ICAM-1 (APC-conjugated anti-human ICAM-1) was assessed 
using flow cytometry. HAECs were treated with a BMP6 neutralising antibody (BMP6 Ab) 60 min prior 
to the addition of BMP9 (5ng/ml, 16h) followed by TNFα (0.05ng/ml, 4 hours). Surface expression of (D) 
E-selectin (FITC-conjugated anti-human E-selectin), (E) VCAM-1 (PE-Cy5-conjugated anti-human 
VCAM-1) and (F) ICAM-1 (APC-conjugated anti-human ICAM-1) was assessed using flow cytometry. 
HAECs were treated with a BMP6 neutralising antibody (BMP6 Ab) 60 min prior to the addition of 
BMP10 (5ng/ml, 16h) followed by TNFα (0.05ng/ml, 4 h). Surface expression of (G) E-selectin (FITC-
conjugated anti-human E-selectin), (H) VCAM-1 (PE-Cy5-conjugated anti-human VCAM-1) and (I) 
ICAM-1 (APC-conjugated anti-human ICAM-1) was assessed using flow cytometry. Forward scatter and 
side scatter gating was applied to the HAEC population. Data are shown as median fluorescence intensity 
(MFI) expressed as fold change relative to untreated HAECs Experiments were performed in triplicate 
and the data are representative of n=3 biological repeats. Error bars represent ± S.E.M. *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001, ns=not significant. 
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FIGURE 4. Effect of ALK1 and ALK2 siRNA on BMP9- and BMP10-induced upregulation of E-
selectin, VCAM-1 and ICAM-1 in TNFα-stimulated human aortic endothelial cells (HAECs). 
HAECs were siRNA transfected, then treated with BMP9 or BMP10 (5ng/ml; 16 h) prior to TNFα 
treatment (0.05ng/ml for 4 hours). Surface expression of (A) E-selectin (FITC-conjugated anti-human E-
selectin), (B) VCAM-1 (PE-Cy5-conjugated anti-human VCAM-1) and (C) ICAM-1 (APC-conjugated 
anti-human ICAM-1) was assessed using flow cytometry. Forward scatter and side scatter gating was 
applied to the HAEC population. Data is shown as median fluorescence intensity (MFI) expressed as fold 
change relative to HAECs transfected with siRNA control pool (siCP). Experiments were performed in 
triplicate and the data are representative of n=3 biological repeats. Error bars represent ± S.E.M.  ***P ≤ 
0.001. 
 
FIGURE 5. LDN193189 reduces the BMP9- and BMP10-induced upregulation of E-selectin, 
VCAM-1 and ICAM-1 and monocyte recruitment in TNFα-stimulated human aortic endothelial 
cells (HAECs). HAECs were pre-treated with LDN193189 (250 nM resuspended in DMSO), DMSO, 
then stimulated with BMP9 or BMP10 (5ng/ml; 16 h) prior to TNFα treatment (0.05ng/ml for 4 hours). 
Surface expression of (A) E-selectin (FITC-conjugated anti-human E-selectin), (B) VCAM-1 (PE-Cy5-
conjugated anti-human VCAM-1) and (C) ICAM-1 (APC-conjugated anti-human ICAM-1) was assessed 
using flow cytometry. Forward scatter and side scatter gating was applied to the HAEC population. Data 
are shown as median fluorescence intensity (MFI) expressed as fold change relative to HAECs transfected 
with siRNA control pool (siCP). (D) HAECs were treated as described above and then monocytes were 
perfused in a flow adhesion assay. (E) Monocyte behaviour (rolling – clear bar, adherence –grey bar and 
transmigration – black bar) was expressed as a percentage of total recruitment. Experiments were 
performed in triplicate and the data are representative of n=3 biological repeats. Error bars represent ± 
S.E.M. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
 
FIGURE 6. Knockdown of BMPR2 and ACVR2A inhibits the BMP9- and BMP10-induced 
upregulation of E-selectin, VCAM-1 and ICAM-1 in TNFα-stimulated human aortic endothelial 
cells (HAECs). HAECs were siRNA transfected, then treated with BMP9 or BMP10 (5ng/ml; 16 h) prior 
to TNFα treatment (0.05ng/ml; 4 h). Surface expression of (A) E-selectin (FITC-conjugated anti-human 
E-selectin), (B) VCAM-1 (PE-Cy5-conjugated anti-human VCAM-1) and (C) ICAM-1 (APC-conjugated 
anti-human ICAM-1) was assessed using flow cytometry. Forward scatter and side scatter gating was 
applied to the HAEC population. Data are expressed as median fluorescence intensity (MFI) expressed as 
fold change relative to HAECs transfected with siRNA control pool (siCP). Experiments were performed 
in triplicate and the data are representative of n=3 biological repeats. Error bars represent ± S.E.M.  *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001. 
 
FIGURE 7. Smad1 and Smad5 mediate the BMP9- and BMP10-induced upregulation of E-selectin, 
VCAM-1 and ICAM-1 in TNFα-stimulated human aortic endothelial cells (HAECs). HAECs were 
siRNA transfected, then treated with BMP9 or BMP10 (5ng/ml, 16 h) prior to TNFα treatment 
(0.05ng/ml, 4 h). Surface expression of (A) E-selectin (FITC-conjugated anti-human E-selectin), (B) 
VCAM-1 (PE-Cy5-conjugated anti-human VCAM-1) and (C) ICAM-1 (APC-conjugated anti-human 
ICAM-1) was assessed using flow cytometry. Forward scatter and side scatter gating was applied to the 
HAEC population. Data are shown as median fluorescence intensity (MFI) expressed as fold change 
relative to HAECs transfected with siRNA control pool (siCP). Experiments were performed in triplicate 
and the data are representative of n=3 biological repeats. Error bars represent ± S.E.M. *P ≤ 0.05, **P ≤ 
0.01, ***P≤ 0.001. 
 
FIGURE 8. BMP9 and BMP10 increase IκB-α protein levels in human aortic endothelial cells 
(HAECs). HAECs were treated with BMP9 or BMP10 (5ng/ml, 16 h) prior to TNFα treatment 
(0.05ng/ml) for 15 min or 30 min. (A) Protein lysates were immunoblotted for IκB-α, phospho-Ser32/36-
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IκB-α (P-IκB-α), p65/RelA (p65) or phospho-Ser536-p65 (P-p65). All blots were reprobed for α-tubulin 
to confirm equal loading. Blots are representative of n=3 separate experiments. (B) Densitometry was 
determined using ImageJ for the three IκB-α blots, each band being expressed as a ratio of IκB-α/α-
tubulin. These ratios were then normalised to the 0.1% control for the relevant time point.   
 
 
FOOTNOTES 
The abbreviations used are: BMP9, BMP10, TGFβ, TNFα, HAECs, NF-κB 
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